Details for Patent: 8,263,581

Which drugs does patent 8,263,581 protect, and when does it expire?

Patent 8,263,581 protects QUZYTTIR and is included in one NDA.

This patent has five patent family members in five countries.

Summary for Patent: 8,263,581

Title:	Non-sedating antihistamine injection formulations and methods of use thereof
Abstract:	Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute allergic reactions including anaphylaxis with the compositions are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms. In other embodiments, the non-sedating or second and third generation antihistamine injectable formulations are therapeutically equivalent to diphenhydramine injectable formulations and/or are more effective than placebo. In other embodiments, a non-sedating antihistamine injectable composition is delivered by an autoinjector.
Inventor(s):	Du; Jie (Lansdale, PA)
Assignee:	JDP Therapeutics, Inc. (Lansdale, PA)
Application Number:	12/704,089
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 8,263,581

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Jdp	QUZYTTIR	cetirizine hydrochloride	SOLUTION;INTRAVENOUS	211415-001	Oct 4, 2019		RX	Yes	Yes						TREATMENT OF ACUTE URTICARIA

International Family Members for US Patent 8,263,581

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010266103
Canada	2803987
European Patent Office	2477634
Spain	2616703
World Intellectual Property Organization (WIPO)	2011003074